Gastrointestinal peptides and bone health

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 1, 2010, Pages 44-50

  Wong, Iris P L ^a   Baldock, Paul A ^a   Herzog, Herbert ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Anorexia; Bone; Diabetes; Gastrointestinal peptide; Obesity

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ADRENOMEDULLIN; AMYLIN; AMYLIN DERIVATIVE; CHOLECYSTOKININ; DEVAZEPIDE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; PANCREAS HORMONE; PANCREAS POLYPEPTIDE; PEPTIDE YY; PRAMLINTIDE; PREPTIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

BONE DENSITY; BONE DEVELOPMENT; DEPRESSION; EWING SARCOMA; HEALTH; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL RESEARCH; NONHUMAN; NORRIE DISEASE; PHYSIOLOGY; REGULATORY MECHANISM; REVIEW;

ADRENOMEDULLIN; AMYLOID; ANIMALS; BONE AND BONES; BONE REMODELING; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON-LIKE PEPTIDES; HOMEOSTASIS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; PANCREATIC POLYPEPTIDE; PEPTIDE FRAGMENTS; PEPTIDE YY; SEROTONIN;

EID: 75149144404     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283344a05     Document Type: Review

References (84)

1. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
2. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clinical Endocrinol Metab 2001; 86:4753-4758.
3. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50:1714-1719.
4. Williams DL, Cummings DE, Grill HJ, Kaplan JM. Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 2003; 144:2765-2767.
5. Ohlsson C, Bengtsson BA, Isaksson OG, et al. Growth hormone and bone. Endocr Rev 1998; 19:55-79.
6. Fukushima N, Hanada R, Teranishi H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res 2005; 20:790-798.
7. Maccarinelli G, Sibilia V, Torsello A, et al. Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 2005; 184:249-256.
8. Kim SW, Her SJ, Park SJ, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone 2005; 37:359-369.
9. Delhanty PJ, van der Eerden BC, van der Velde M, et al. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol 2006; 188:37-47.
10. Wang DH, Hu YS, Du JJ, et al. Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine 2009; 35:112-117.
11. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23:7973-7981.
12. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 2004; 101:4679-4684.
13. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87:240-244.
14. Misra M, Miller KK, Tsai P, et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006; 91:1027-1033. (Pubitemid 43357776)
15. Misra M, Prabhakaran R, Miller KK, et al. Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. J Clin Endocrinol Metab 2008; 93:1292-1297.
16. Pacifico L, Anania C, Poggiogalle E, et al. Relationships of acylated and desacyl ghrelin levels to bone mineralization in obese children and adolescents. Bone 2009; 45:274-279.
17. Jurimae J, Cicchella A, Tillmann V, et al. Effect of pubertal development and physical activity on plasma ghrelin concentration in boys. J Endocrinol Invest 2009; 32:18-22.
18. Sowers MR, Wildman RP, Mancuso P, et al. Change in adipocytokines and ghrelin with menopause. Maturitas 2008; 59:149-157.
19. Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med 1993; 202:44-63.
20. Wortley KE, Garcia K, Okamoto H, et al. Peptide YY regulates bone turnover in rodents. Gastroenterology 2007; 133:1534-1543.
21. Baldock PA, Sainsbury A, Couzens M, et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109:915-921.
22. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
23. Reid IR. Relationships among body mass, its components, and bone. Bone 2002; 31:547-555.
24. Stock S, Leichner P, Wong AC, et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005; 90:2161-2168.
25. Utz AL, Lawson EA, Misra M, et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 2008; 43:135-139.
26. Russell M, Stark J, Nayak S, et al. Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and nonathletic controls. Bone 2009; 45:104-109.
27. Hosaka H, Nagata A, Yoshida T, et al. Pancreatic polypeptide is secreted from and controls differentiation through its specific receptors in osteoblastic MC3T3-E1 cells. Peptides 2008; 29:1390-1395.
28. Sainsbury A, Baldock PA, Schwarzer C, et al. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 2003; 23:5225-5233.
29. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107:513-523.
30. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDLreceptor-related protein 5. N Engl J Med 2002; 346:1513-1521.
31. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptorrelated protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11-19.
32. Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002; 157:303-314.
33. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8:751-764.
34. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005; 280:21162-21168.
35. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008; 135:825-837.
36. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:1240-1245.
37. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188-194.
38. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351:1303-1307.
39. Warden SJ, Robling AG, Sanders MS, et al. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005; 146:685-693.
40. Martinez A, Weaver C, Lopez J, et al. Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology 1996; 137:2626-2632.
41. Cornish J, Callon KE, Cooper GJ, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 1995; 207:133-139.
42. Cornish J, Callon KE, Bava U, et al. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 2001; 29:162-168.
43. Cornish J, Callon KE, King AR, et al. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 1998; 275 (4 Pt 1):E694-E699.
44. Horcajada-Molteni MN, Davicco MJ, Lebecque P, et al. Amylin inhibits ovariectomy-induced bone loss in rats. J Endocrinol 2000; 165:663-668.
45. Horcajada-Molteni MN, Chanteranne B, Lebecque P, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 2001; 16:958-965.
46. Guzel S, Gunes N, Yildiz H, Yilmaz B. Effects of amylin on bone development and egg production in hens. Poult Sci 2009; 88:1719-1724.
47. Dacquin R, Davey RA, Laplace C, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004; 164:509-514.
48. Davey RA, Moore AJ, Chiu MW, et al. Effects of amylin deficiency on trabecular bone in young mice are sex-dependent. Calcif Tissue Int 2006; 78:398-403.
49. Schwartz AV. Diabetes mellitus: does it affect bone? Calcif Tissue Int 2003; 73:515-519.
50. Bronsky J, Prusa R. Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos Int 2004; 15:243-247.
51. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE. Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 1998; 275 (5 Pt 1):E785-E791.
52. Borm AK, Klevesath MS, Borcea V, et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 1999; 31:472-475.
53. Cornish J, Callon KE, Coy DH, et al. Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. Am J Physiol 1997; 273 (6 Pt 1): E1113-E1120.
54. Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A 2001; 98:615-619.
55. Naot D, Callon KE, Grey A, et al. A potential role for adrenomedullin as a local regulator of bone growth. Endocrinology 2001; 142:1849-1857.
56. Hamada H, Kitamura K, Chosa E, et al. Adrenomedullin stimulates the growth of cultured normal human osteoblasts as an autocrine/paracine regulator. Peptides 2002; 23:2163-2168.
57. Cornish J, Grey A, Callon KE, et al. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. Biochem Biophys Res Commun 2004; 318:240-246.
58. Uzan B, Villemin A, Garel JM, Cressent M. Adrenomedullin is antiapoptotic in osteoblasts through CGRP1 receptors and MEK-ERK pathway. J Cell Physiol 2008; 215:122-128.
59. Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 2001; 360 (Pt 2):431-439.
60. Cornish J, Callon KE, Bava U, et al. Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo. Am J Physiol 2007; 292:E117-E122.
61. Liu YS, Lu Y, Liu W, et al. Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts. Amino Acids 2009. [Epub ahead of print]
62. Khosla S, Ballard FJ, Conover CA. Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab 2002; 87:3867-3870.
63. Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000; 141:1228-1235. (Pubitemid 32260466)
64. Zhong Q, Itokawa T, Sridhar S, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol 2007; 292:E543-E548.
65. Ding KH, Shi XM, Zhong Q, et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 2008; 23: 536-543.
66. Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001; 177:35-41.
67. Xie D, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptideoverexpressing transgenic mice have increased bone mass. Bone 2007; 40:1352-1360.
68. Xie D, Cheng H, Hamrick M, et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005; 37:759-769.
69. Tsukiyama K, Yamada Y, Yamada C, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol 2006; 20:1644-1651.
70. Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18:2180-2189.
71. Henriksen DB, Alexandersen P, Byrjalsen I, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004; 34:140-147.
72. Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 2007; 40:723-729.
73. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45:833-842.
74. Holst JJ, Hartmann B, Gottschalck IB, et al. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scand J Gastroenterol 2007; 42:814-820.
75. Gottschalck IB, Jeppesen PB, Hartmann B, et al. Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol 2008; 43:1304-1310.
76. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009; 2009:616054.
77. Yamada C, Yamada Y, Tsukiyama K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008; 149:574-579.
78. Crespel A, De Boisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology 1996; 137:3674-3680.
79. Lamari Y, Boissard C, Moukhtar MS, et al. Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagonlike peptide 1. FEBS Lett 1996; 393:248-252.
80. Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 2009; 84:453-461.
81. Nuche-Berenguer B, Moreno P, Portal-Nunez S, et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept 2009. [Epub ahead of print]
82. Wank SA. Cholecystokinin receptors. Am J Physiol 1995; 269 (5 Pt 1): G628-G646.
83. Carrillo J, Garcia-Aragoncillo E, Azorin D, et al. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 2007; 13:2429-2440.
84. Carrillo J, Agra N, Fernandez N, et al. Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. Anticancer Drugs 2009; 20:527-533.